TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06080919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug coated-balloon percutaneous coronary intervention.
Description: Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography-derived coronary physiology (IMRangio)
Description: Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
Study: NCT05530460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retinal imaging with low-cost OCT device
Description: Retinal imaging with low-cost OCT device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retinal imaging with commercial OCT device
Description: retinal imaging with commercial OCT device
Study: NCT05668000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bluetooth-connected monitoring devices and a feedback system
Description: AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system
Study: NCT04844034

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-EPA multinutrient supplement.
Description: Three capsules with the largest meal of the day providing:~* 1,125 mg EPA~* 441 mg DHA~* 330 mg Magnesium~* 7.5 mg a-tocopherol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules with the largest meal of the day providing:~* 3,060 mg sunflower seed oil~* 60 mg lecithin~* 300 mg glyceryl monostearate~* 465 mg EPA/DHA (18%/12% respectively for blinding)
Study: NCT04807309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol Pill
Description: Danazol 200 mg orally twice a day
Study: NCT05668000

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile application
Description: The mobile application provide only self-management interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The mobile application provide only self-management interventions.
Study: NCT05311774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: tablet
Study: NCT04807309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day
Study: NCT04466761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosaccharide Powder
Description: Monosaccharide powder dissolved in water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo (cellulose powder).
Study: NCT05036577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
Study: NCT05778838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
Study: NCT05465538

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]UCB-J PET
Description: Single PET scan using the radioligand \[11C\]UCB-J

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]UCB-J PET
Description: Single PET scan using the radioligand \[11C\]UCB-J
Study: NCT04791319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab will be administered subcutaneously.
Study: NCT06478433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Munatoril Aerosol Combo
Description: Munatoril® Aerosol Combo is a Medical Device that contains:~5 ml single-dose vials of sterile, 3% hypertonic, near-neutral pH bromine-iodine saline solution, based on Cervia integral sea salt, salso-bromo-iodine saline mother water from the Cervia Thermal Baths and hyaluronic acid with high molecular weight.~Lavonase® syringe with blue nebulizer valve (microsol), 10 ml, Medical Device for the administration of solutions in nebulized form within the nasal cavities and nasopharynx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iperclenny
Description: Hypertonic and Isotonic solution present on market in italy.
Study: NCT05311774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT04620733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg
Description: Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for double-blind period, for a duration of up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg
Description: If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
Study: NCT06094842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT04982211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol hydrochloride capsules, dosed per participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol hydrochloride capsules, dosed per participant weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules, dosed per participant weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules, dosed per participant weight
Study: NCT04921592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity stimulation
Description: transcutaneous stimulation of the upper extremities
Study: NCT05854654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air Leaks
Description: The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study.
Study: NCT05258656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
Study: NCT04696185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG
Description: Dapagliflozin 10 mg (daily oral dose)
Study: NCT06437197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Removal of the coronal pulp chamber in an adult teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Removal of the coronal pulp chamber in an adult teeth
Study: NCT05562947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS With Ranibizumab (100 mg/mL)
Description: Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (10 mg/mL)
Description: Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
Study: NCT04804098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)
Description: Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)
Description: Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
Study: NCT06645938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment A)
Description: Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment A)
Description: Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment B)
Description: Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment B)
Description: Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
Study: NCT06291883

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Kang Guan Recipe (Treat)
Description: Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Kang Guan Recipe (Placebo)
Description: Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.
Study: NCT05344183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-level laser
Description: A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
Study: NCT05006157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViaOne device
Description: ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
Study: NCT04457089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
Study: NCT05722925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET/CT
Description: 8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
Study: NCT05722535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Media Check-In (FMC)
Description: An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
Study: NCT05048433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: implementation strategy for active learning to promote physical activity
Description: The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Implementation support
Description: Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
Study: NCT04740385

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung auscultation
Description: auscultation of air entry through chest wal
Study: NCT05418582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 and intraconazole
Description: All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 and carbamazepine
Description: All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
Study: NCT04102254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANT recording and stimulation
Description: In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
Study: NCT06094842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridge Therapy
Description: Undergo bridging therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05183854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 20-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 20-valent Conjugate Vaccine
Description: Given IM
Study: NCT04740385

Intervention type: DEVICE
Intervention: Fiberoptic bronchoscopy
Description: Checking correct double lumen position through direct vision using fiberoptic bronchoscopy

Intervention type: DEVICE
Intervention: Lung Ultrasound
Description: real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
Study: NCT05710185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: See arm/group description
Study: NCT06094842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06009107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HY004
Description: A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Administered intravenously.
Study: NCT04229329

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intensive Finger Individuation Therapy
Description: Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Intensive non-directed finger movement therapy
Description: Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
Study: NCT02586831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: 2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: 1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
Study: NCT05183854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polyvalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polyvalent Vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06389877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM-302
Description: BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD